Here's how NCBI.NLM.NIH.GOV makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

NCBI . NLM . NIH . GOV {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Ncbi.nlm.nih.gov Make Money
  6. Keywords
  7. Topics
  8. Questions
  9. Social Networks
  10. External Links
  11. Analytics And Tracking
  12. Libraries
  13. Hosting Providers
  14. CDN Services

We began analyzing https://pmc.ncbi.nlm.nih.gov/articles/PMC3736134/, but it redirected us to https://pmc.ncbi.nlm.nih.gov/articles/PMC3736134/. The analysis below is for the second page.

Title[redir]:
Cancer heterogeneity—a multifaceted view - PMC
Description:
Cancers of various organs have been categorized into distinct subtypes after increasingly sophisticated taxonomies. Additionally, within a seemingly homogeneous subclass, individual cancers contain diverse tumour cell populations that vary in ...

Matching Content Categories {📚}

  • Science
  • Health & Fitness
  • Education

Content Management System {📝}

What CMS is ncbi.nlm.nih.gov built with?

Custom-built

No common CMS systems were detected on Ncbi.nlm.nih.gov, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of ncbi.nlm.nih.gov audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Ncbi.nlm.nih.gov Make Money? {💸}

We don't see any clear sign of profit-making.

Not every website is profit-driven; some are created to spread information or serve as an online presence. Websites can be made for many reasons. This could be one of them. Ncbi.nlm.nih.gov has a secret sauce for making money, but we can't detect it yet.

Keywords {🔍}

cancer, doi, pubmed, google, scholar, cell, tumour, cells, heterogeneity, stem, pmc, article, mutations, tumours, free, subtypes, nature, clinical, cancers, therapy, breast, genetic, cscs, csc, distinct, patients, clonal, colon, dna, evolution, molecular, presence, treatment, resistance, growth, drug, differentiated, colorectal, genes, methylation, intestinal, gene, crucial, phenotype, present, identification, nat, individual, human, kras,

Topics {✒️}

adenomatous polyposis coli c-kit c-met estrogen-receptor-positive tumors bcr–abl kras oncogene braf oncogene emt–csc programme oestrogen receptor antagonist factor oestrogen receptor maintain mesenchymal notch ligands dll4 nfκb drive tumour growth specific growth factors anti-her2 monoclonal antibody myofibroblasts produce hgf pmc beta search tumour growth tumour suppressor mlh1 light blue growth advantage mammary stem cells tgf-β potently induces light grey pdgfr-α mutations human leukemia similarly tgf-β triggers mammary tumour metastasis chronic lymphocytic leukemia chronic myelogenous leukemia abl gene committed granulocyte–macrophage progenitors cutaneous t-cell lymphoma hgf poor-prognosis braf-mutant tumor cell populations obtain multi-regional sampling cancer-stem-cell research mlh1 methylation tumorigenic breast-cancer cells primary tumor genotype breast tumor heterogeneity node-negative breast cancer primary tumour-derived material abl kinase cancer stem cells—perspectives her2 subtype stroma-derived prognostic profile

Questions {❓}

  • Are cancer subtypes suitably evaluated during clinical trials?
  • Assuming the latter is true, how do we progress towards more effective treatments (Sidebar A)?
  • Can one find analogy between these two forms of heterogeneity that could be exploited to improve rational therapy design?
  • Could we approach clonal variation sequentially in the clinic, targeting one subclone at a time and following their evolution?
  • Is the cancer stem cell state a fixed quality?
  • The question remains, however, of whether these diverse issues are rate-limiting steps that need to be resolved to improve clinical outcome for patients?
  • What are the best models to recapitulate most of the heterogeneity found in primary tumours and which can also be easily used for pre-clinical drug testing?
  • What are the common biological backgrounds between patients from a given subtype?
  • What is the evolutionary benefit of a single or combination of genetic hits on normal stem cells?

Social Networks {👍}(6)

External Links {🔗}(205)

Analytics and Tracking {📊}

  • Google Analytics
  • Google Analytics 4
  • Google Tag Manager

Libraries {📚}

  • jQuery
  • jQuery module (jquery-3.6.0)
  • Zoom.js

Emails and Hosting {✉️}

Mail Servers:

  • nihcesxway.hub.nih.gov
  • nihcesxway2.hub.nih.gov
  • nihcesxway3.hub.nih.gov
  • nihcesxway4.hub.nih.gov
  • nihcesxway5.hub.nih.gov

Name Servers:

  • dns1-ncbi.ncbi.nlm.nih.gov
  • dns2-ncbi.ncbi.nlm.nih.gov
  • lhcns1.nlm.nih.gov
  • lhcns2.nlm.nih.gov

CDN Services {📦}

  • Ncbi

3.81s.